Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Pulmonary Arterial Hypertension
Phase PHASE3
Enrollment 20
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is: • if preservative-free parenteral treprostinil is safe and tolerable in the treatment of paediatric PAH in patients who are either prostacyclin-naïve or have been previously treated with commercially available parenteral treprostinil formulations. Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week).

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: preservative-free parenteral treprostinil — Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.

Primary Outcomes

  • Frequency and seriousness of adverse events and adverse drug reactions (5 months (20 weeks ± 1 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-07-31
Completion: 2028-11
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AOP Orphan Pharmaceuticals AG
Contact Information
Study Contact:
Clinical Project Manager
4366488375206
trepaed@aop-health.com
Sulaimi Albinni, MD
Medizinische Universität Wien
Damien Bonnet, Prof
Necker-Enfants Malades Hospital, Paris
Interventions
  • Drug: preservative-free parenteral treprostinil — Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
Study Locations (5 sites)
Medizinische Universität Wien, Vienna, State of Vienna 1090 Austria
Necker-Enfants Malades Hospital, Paris, Paris, Paris 75015 France
Gottsegen National Cardiovascular Center, Budapest, Budapest H-1096 Hungary
Pediatric Cardiac Center, Bratislava, Slovakia
Ramón y Cajal University Hospital, Madrid, Madrid 28034 Spain
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent by the parents or the legal representatives and written assent from appropriately aged participants 2. Males or females from birth to under 18 years of age at the time informed consent was signed 3. Confirmed diagnosis of severe PAH classified as PH Group 1 requiring a treatment with prostacyclin infusion 4. Current diagnosis of PAH confirmed by right heart catheterisation (RHC) at screening or by historical RHC prior to screening with following haemodynamic findings: * Mean pulmonary arterial pressure (mPAP) \>20 mmHg * Pulmonary vascular resistance Index (PVRI) \>3 Wood Units (WU) m² If RHC is not possible due to medical reasons (e.g. neonates and infants), the confirmation by ECHO at the screening is sufficient. 5. Prostacyclin naïve or patients pre-treated with SC or IV treprostinil prior to screening 6. A subject is eligible to participate in this study, as assessed by the investigator, if they are of: * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or, * Child-bearing potential - has a negative pregnancy test and is not lactating and, if sexually active, agrees to continue to use 2 reliable methods of contraception until study completion and for at least 30 days following the last dose of study drug. Examples of reliable birth control methods include true abstinence as a lifestyle choice (periodic sexual abstinence method is not acceptable); the use of oral contraceptives; a reliable barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices) Exclusion Criteria: 1. Known intolerance to prostacyclin analogues 2. PH related to conditions other than specified above 3. Unrepaired congenital heart disease if surgery is planned within next 5 months 4. Subjects diagnosed with any lung disease 5. Acutely decompensated heart failure within previous 30 days from screening 6. Subjects who have had an atrial septostomy or potts shunt within the previous 6 months of screening 7. Any clinically significant laboratory abnormality that precludes initiation or continuation of treprostinil therapy 8. Moderate to severe hepatic dysfunction as defined by elevated liver function tests (aspartate aminotransferase or alanine aminotransferase) ≥3 times the upper limit of normal at Screening, or Child Pugh class B or C hepatic disease 9. Subjects who are pregnant or breastfeeding 10. Haematological abnormalities (e.g., severe anaemia, Hgb \<10 g/dL, leukopenia, White Blood Cells (WBC) \<2500/μL) 11. History of substance use disorder, unless a proof of abstinence ≥1 year is provided 12. Other concurrent severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study 13. Participation in another clinical trial of an investigational drug or device (including with placebo) within 30 days or 5 half-lives prior to screening, which-ever is longer 14. Patients not able to handle pumps and infusion site if there is no parent, family member, guardian present in their household taking over pump handling or if they are not treated in hospital set-up
Conditions Postpartum Depression, Insomnia, Stress
Phase NA
Enrollment 114
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Improving maternal mental health is a worldwide health priority. Nevertheless, several scientific sources highlighted lack of empirical data which could drive clinical practice. The present project addresses psychobiological mechanisms leading to peripartum mental disorders. It focuses on one key risk factor for psychopathology, which is poor sleep continuity. The project aims to describe the link between maternal poor sleep quality and the cascade of events which may enhance vulnerability to stress and risk for mental disorders and to evaluate the efficacy of an online automated psychological prenatal intervention directed to sleep problems in preventing these negative outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Improving sleep health and resilience during pregnancy — Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician. Sessions' contents: 1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy; 2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques; 3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques; 4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques; 5. Sleep in the postpartum and the development of sleep regulation in children; 6. Relapse prevention and focus on acquired skills and how to prioritize sleep.
  • Behavioral: Information on pregnancy-related issues — Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician. Sessions will cover the following contents: Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions.

Primary Outcomes

  • Stress reactivity (Twice a day (morning and evening) once at baseline; after 6 weeks from baseline; 6 months post-partum)
  • Sleep efficiency (One week at baseline; after 6 weeks from baseline; 6 months post-partum)
  • Depressive symptoms (Baseline; after 6 weeks from baseline; after 12 weeks from baseline; 1-to-2-week after birth; 3 months post-partum; 6 months post-partum)
  • Insomnia symptoms (Baseline; after 6 weeks from baseline; after 12 weeks from baseline; 1-to-2-week after birth; 3 months post-partum; 6 months post-partum)
  • Anxiety symptoms (Baseline; after 6 weeks from baseline; after 12 weeks from baseline; 1-to-2-week after birth; 3 months post-partum; 6 months post-partum)
  • Valence of affective states (Baseline; after 6 weeks from baseline; after 12 weeks from baseline; 1-to-2-week after birth; 3 months post-partum; 6 months post-partum)
  • Arousal of affective states (Baseline; after 6 weeks from baseline; after 12 weeks from baseline; 1-to-2-week after birth; 3 months post-partum; 6 months post-partum)
  • Emotion regulation (Baseline; after 6 weeks from baseline; 6 monhts post-partum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-06
Completion: 2026-10-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 114 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Rome G. Marconi
Collaborators: University of Bologna, University of the Italian Switzerland
Principal Investigators:
  • Chiara Baglioni, Professor (STUDY_DIRECTOR) - Department of Human Sciences, Guglielmo Marconi University, Rome, Italy
Contact Information
Study Contact:
Chiara Baglioni, PhD
06377251
c.baglioni@unimarconi.it
Debora Meneo, M.Sc
06377251
d.meneo@unimarconi.it
Viviana Lo Martire
viviana.lomartire2@unibo.it
Department of Biomedical and Neuromotor Sciences, Physiology campus, University of Bologna, Bologna, Italy
Interventions
  • Behavioral: Improving sleep health and resilience during pregnancy — Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician. Sessions' contents: 1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy; 2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques; 3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques; 4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques; 5. Sleep in the postpartum and the development of sleep regulation in children; 6. Relapse prevention and focus on acquired skills and how to prioritize sleep.
  • Behavioral: Information on pregnancy-related issues — Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician. Sessions will cover the following contents: Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions.
Study Locations (2 sites)
Department of Biomedical and Neuromotor Sciences, Physiology campus, University of Bologna, Bologna, Italy, Bologna, Bologna 40126 Italy
Department of Human Sciences, Guglielmo Marconi university, Rome, Rome 00193 Italy
Eligibility Criteria
Inclusion Criteria: 1. age ≥ 18 yrs. old; 2. good knowledge of Italian language; 3. intention to continue pregnancy; 4. BMI ranging 18-30 (i.e., without underweight or obesity following international criteria; WHO, 2013); 5. ≤ 15th week of pregnancy at the time of recruitment. Exclusion Criteria: 1. severe diagnosis of relevant somatic disorder; 2. smoking; 3. alcohol intake; 4. assumption of illegal drugs;
Conditions Breast Cancer
Phase Not Applicable
Enrollment 234
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Expand the current evidence base regarding percutaneous cryoablation of early-stage, low-risk breast tumors, integrated into the standard therapeutic pathway with well-defined follow-up data, as well as data on quality of life. Demonstrate, therefore, that the use of percutaneous cryoablation in the treatment of low-risk breast carcinoma is not inferior to surgery when combined with adjuvant radiotherapy and chemotherapy (when necessary). The hypothesis is that cryoablation, being simple and oncologically effective, ensures a better quality of life for the patient (reduced morbidity, no need for general anesthesia, improved cosmetic outcomes) and consequently has a lesser psychological impact, as well as a better cost-benefit ratio compared to the standard surgical approach.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Cryoablation — Percutaneous Cryoablation of Breast Cancer

Primary Outcomes

  • Procedure failure rate (8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-15
Completion: 2031-03-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 234 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Collaborators: Fondazione Umberto Veronesi, IceCure Medical Ltd.
Principal Investigators:
  • Franco Orsi, MD (PRINCIPAL_INVESTIGATOR) - European Institute of Oncology
Contact Information
Study Contact:
Paolo Della Vigna, MD
0039 02 57489060
paolo.dellavigna@ieo.it
Mara Negri
0039 02 57489536
mara.negri@ieo.it
Franco Orsi
European Institute of Oncology
Interventions
  • Procedure: Cryoablation — Percutaneous Cryoablation of Breast Cancer
Study Locations (1 sites)
European Institute of Oncology, Milan, Italy
Eligibility Criteria
Inclusion Criteria: * Tumour, Node, Metastasis stage (TNM) = dimension up to 15 mm as measured by breast ultrasound, MRI, Mammography, Node negative, absence of distant metastasis * Unifocality * All invasive cancer, except lobular * Biology= luminal A and luminal B\* (Estrogen Receptor (ER) positive/human epidermal growth factor receptor-2 (HER2)negative) (Documented estrogen receptor (ER)-positive tumor assessed locally and defined as ≥10% of tumor cells stained positive. Documented HER2-negative tumor (in accordance to 2018 American Society of Clinical Oncology guidelines, as determined per local assessment) * Any grade (G) * Radiological detection= breast ultrasound, MRI, Mammography * Tumor site= not located superficially (≥1 cm from the skin plane) * Breast size= any, appropriate for the procedure in relation to ultrasound examination * Referral to breast cryoablation by a multidisciplinary tumor board * Planned treatment with cryoablation using IceCure (TM-trade mark) system * Informed consent \*Luminal B and G3 BC: previous specific patients' selection and Oncotype Dx \[31\] on cancer tissue from needle biopsy before procedure and eventual Prediction Analysis of Microarray 50 (PAM50) test. Exclusion Criteria: * Plurifocality * Invasive lobular breast cancer * HER2 overexpressed or Triple Negative Breast Cancer (TNBC) * tumor dimension \>15 mm * Node positive * post NeoAdjuvant ChemoTherapy (NACT) breast cancer * \<50 years * Presence of intraductal component (DCIS) * Absence of psychological compliance in understanding and adhering to rationale of the study * Inability to perform MRI * Breast augmentation with implants
Conditions HER2-positive Breast Cancer
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: GeoMx data analysis with clinical outcome — 1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome

Primary Outcomes

  • Spatial transcriptomic analysis (Before chemotherapy, curative surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-18
Completion: 2027-12-31
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samsung Medical Center
Contact Information
Study Contact:
Ji-Yeon Kim
82-2-3410-3459
jyeon25@skku.edu
MIRYOUNG HONG
82-2-2148-7147
ring7629@naver.com
Ji-Yeon Kim
82-2-3410-3459
jyeon25@skku.edu
Ji-Yeon Kim
Interventions
  • Diagnostic Test: GeoMx data analysis with clinical outcome — 1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome
Study Locations (1 sites)
Ji-Yeon Kim, Seoul, 06351 South Korea
Eligibility Criteria
Inclusion Criteria: * HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples Exclusion Criteria: * TNBC breast cancer * Hormone receptor positive breast cancer * Non-available FFPE samples * Treated except T-Dxd
Conditions Chronic Low Back Pain, Depression
Phase PHASE2
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a pilot study to evaluate the feasibility, acceptability, and safety of ketamine infusions followed by a brief behavioral intervention in Veterans with chronic low back pain and depression.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Drug: Ketamine hydrochloride — Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
  • Behavioral: Minimally Enhanced Usual Care — Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
  • Behavioral: Brief narrative intervention — Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions. Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention.

Primary Outcomes

  • Pain Interference (PROMIS Short Form v1.1 Pain Interference 6b) (Visit 7 (8-10 days post randomization))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-12-03
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Victoria D Powell, MD (PRINCIPAL_INVESTIGATOR) - VA Ann Arbor Healthcare System, Ann Arbor, MI
Contact Information
Study Contact:
Victoria D Powell, MD
(734) 845-3072
Victoria.Powell2@va.gov
Sarah L Krein, PhD RN
(734) 845-3621
Sarah.Krein@va.gov
Victoria D Powell, MD
734-845-3072
Victoria.Powell2@va.gov
VA Ann Arbor Healthcare System, Ann Arbor, MI
Interventions
  • Drug: Ketamine hydrochloride — Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
  • Behavioral: Minimally Enhanced Usual Care — Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
  • Behavioral: Brief narrative intervention — Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions. Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention.
Study Locations (1 sites)
VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan 48105-2303 United States
Eligibility Criteria
Inclusion Criteria: * Veterans with self-report of moderate to severe, high impact chronic low back pain (defined as 4/10 in severity via NRS, present 3 months on most days) and associated pain interference (defined as T-score 60 on the PROMIS Pain Interference measure), and current significant depressive symptoms (defined as a score 11 on the Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR). * Medically stable (no hospitalizations in the past month lasting 3 days). * No changes in pain or depression medication regimen in 4 weeks. * No planned surgery, injections, hospitalizations, or other new interventions for back pain (except for physical therapy or exercise) or depression during the next four months (study duration). * Participants must have an adult who can drive them home after the ketamine treatments. Exclusion Criteria: * Inability to speak English due to the narrative intervention being conducted in English. * Inability or unwillingness to provide written informed consent (e.g. current delirium). * Current psychotic symptoms, or history of schizophrenia, schizoaffective disorder, and other psychotic disorder. * Currently participating in another clinical trial for pain or depression. * Current uncontrolled hypertension (defined as systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg). * Known elevated intracranial pressure, cerebral arterial aneurysm, or elevated intraocular pressure. * History of cirrhosis or unstable cardiac condition (e.g., decompensated congestive heart failure). * Any of the following lab values \>2x upper limit of normal: alanine transaminase (ALT), aspartate transferase (AST), direct bilirubin, alkaline phosphatase, creatinine; thyroid stimulating hormone (TSH) \<2x lower limit of normal or \>2x upper limit of normal. * Positive urine pregnancy test or lack of birth control method in Veterans of childbearing potential. * Known hypersensitivity to any excipient in the ketamine injection formulation. * Previously experienced serious adverse effects with ketamine. * On day of ketamine infusions, a urine drug screen positive for non-prescribed substances(s) (except cannabis) will exclude a participant from receiving ketamine * Current or previous abuse of ketamine.
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 252
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Although treatments for depression are effective for many people, not everyone responds to treatment. This lack of treatment response could be due, in part, to the presence of multiple underlying causes of people's depression. This study aims to identify subtypes of depression, based on two factors: how successful people perceive themselves to be at regulating their affect in everyday life; and how much activity in the parasympathetic nervous system increases during moments when people try to regulate. The study involves ambulatory assessment of affect, regulation strategies, and physiological activity in everyday life, in a sample of young adults with remitted major depressive disorder and healthy volunteers. We will study regulation responses in the lab to further determine how subtypes differ in neural, physiological, and behavioral responses. Finally, participants will be randomly assigned to a remote, self-administered biofeedback intervention (vs. control intervention) designed to increase parasympathetic activity and physiological regulation success. While engaging in biofeedback at home for 10 days, participants will simultaneously repeat the ambulatory assessments. This design will allow us to determine the proximal impact of biofeedback on indices of regulation success in everyday life, and whether biofeedback has differential impact on regulation success for different subtypes.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Heart rate variability biofeedback — This is a Phase 2 parallel intervention design with random assignment. We will randomly assign participants to one of two biofeedback conditions. Both conditions involve completing breathing exercises at home, 30 minutes per day for 10 days, while receiving continuous feedback about parasympathetic activity from the computer.

Primary Outcomes

  • Physiological regulation success (The two 10-day ambulatory assessment periods.)
  • Average level of heart rate variability (The two 10-day ambulatory assessment periods.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-22
Completion: 2028-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Umiemah Farrukh
2137404503
carlab@usc.edu
Umiemah Farrukh
2137404503
carlab@usc.edu
University of Southern California
Interventions
  • Behavioral: Heart rate variability biofeedback — This is a Phase 2 parallel intervention design with random assignment. We will randomly assign participants to one of two biofeedback conditions. Both conditions involve completing breathing exercises at home, 30 minutes per day for 10 days, while receiving continuous feedback about parasympathetic activity from the computer.
Study Locations (1 sites)
University of Southern California, Los Angeles, California 90089 United States
Eligibility Criteria
Inclusion Criteria for Participants with Remitted Depression: 1. Age 18-27. 2. Meeting criteria for lifetime major depressive disorder. 3. Currently meeting criteria for full remission (absence of clinically significant symptoms) for at least eight weeks, and having a Hamilton Depression Rating Scale score of less than or equal to 7. Inclusion Criteria for Healthy Volunteer Participants: 1. Age 18-27. 2. No lifetime history of any psychiatric disorder. 3. No first-degree relatives with a mood disorder. Exclusion Criteria (same for all participants): 1. Change in psychotropic medication use within the last 30 days 2. Autism spectrum disorder 3. Current eating disorder 4. Intellectual disability 5. Substance use disorder within the past 6 months 6. Contraindications for magnetic resonance imaging or electrocardiogram assessment (e.g., presence of metal in body, claustrophobia, cardiac device, pregnancy).
Conditions Triple Negative Breast Neoplasms
Phase PHASE2
Enrollment 53
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study has as goal to evaluate the use of abemaciclib and bicalutamide in androgen receptor positive metastatic triple negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib — 150 mg tablet orally twice daily
  • Drug: Bicalutamide — 150 mg tablet orally once daily

Primary Outcomes

  • Number of participants with disease control at 16 weeks (Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-08
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Collaborators: Kom Op Tegen Kanker, Eli Lilly and Company, Teva Pharma
Principal Investigators:
  • Patrick Neven, MD, PhD (PRINCIPAL_INVESTIGATOR) - Universitaire Ziekenhuizen KU Leuven
Contact Information
Study Contact:
Patrick Neven, MD, PhD
+3216344750
patrick.neven@uzleuven.be
Kristien Borremans, MD
+321647795
kristien.borremans@kuleuven.be
Kevin Punie, MD
+3234433737
kevin.punie@gza.be
ZAS Augustinus
Interventions
  • Drug: Abemaciclib — 150 mg tablet orally twice daily
  • Drug: Bicalutamide — 150 mg tablet orally once daily
Study Locations (6 sites)
ZAS Augustinus, Antwerp, 2610 Belgium
Antwerp University Hospital, Antwerp, Belgium
University Hospital Brussels, Brussels, Belgium
Ghent University Hospital, Ghent, Belgium
Jessa Ziekenhuis, Hasselt, Belgium
University Hospitals Leuven, Leuven, Belgium
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analysis. If a patient declines to participate in any voluntary exploratory research of the study, there will be no loss of benefit to the patient and she will not be excluded from other aspects of the study 2. Women aged at least 18 years 3. The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic AR+ TNBC 1. AR+ assessed locally and defined as ≥1% of cells staining on IHC of last recurrent/metastatic breast cancer specimen 2. Local biopsy confirmation of last recurrent/metastatic site with positive IHC for ER and/or PR in ≤10% of cells and negative for HER2 per ASCO/CAP-guidelines 3. Prior invasive (metastatic) breast cancer with positive IHC for ER and/or PR in \>10% of cells is allowed, provided the last biopsy of recurrent/metastatic disease has positive IHC for ER and/or PR in ≤10% of cells 4. Prior invasive (metastatic) HER2-positive breast cancer per ASCO/CAP-guidelines is not allowed 5. The patient has measurable disease per RECIST 1.1 or evaluable bone-only disease with lytic or mixed component that is progressive as evidenced on pre-treatment baseline imaging 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks 5. The patient must have had prior treatment with at least 1 prior cytostatic regimen in advanced setting setting unless treatment with a cytostatic regimen is contraindicated as judged by Investigator. There is no upper limit for prior treatment lines in advanced setting. * Patients with known germline BRCA1/2 pathogenic variants should have received previous treatment with PARP inhibitors in the early/locally advanced or metastatic setting, unless contraindicated. * Prior treatment with palbociclib or ribociclib is allowed, provided at least 6 months have elapsed between last administration and start of study treatment 6. Patients must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of prior anticancer treatment except for residual Grade 2 alopecia, anemia or peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and first dose of study drug (provided the patient did not receive radiotherapy). 7. Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization. 8. In females of child-bearing potential, a negative serum or urine pregnancy test within 7 days prior to starting treatment is required. Women of child-bearing potential must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation (in addition to the LHRH-agonist), and for 3 weeks following completion of abemaciclib and for 130 days following completion of bicalutamide. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Exclusion Criteria: 1. Treatment with any of the following: a. Any experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization. b) Currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study. c. Any other chemotherapy, immunotherapy or anticancer agents within 21 days of the first dose of study treatment d. Treatment with palbociclib or ribociclib within 6 months of the first dose of study treatment e. Any prior exposure to abemaciclib f. Any prior exposure to anti-androgen therapy (bicalutamide, abiraterone, and/or enzalutamide) 2. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment 3. Spinal cord compression, leptomeningeal carcinomatosis, or brain metastases - unless asymptomatic, treated, stable at baseline imaging and not requiring corticosteroids \>10 mg prednisolone daily (or equivalent) for at least 2 weeks prior to start of study treatment 4. Concurrent use of endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane, oral contraceptive pills) 5. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 6. As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required. 7. Any of the following cardiac criteria: 1. Mean resting corrected QT interval (QTc) \> 470 msec obtained from 3 consecutive electrocardiograms (ECGs) 2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block) 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval 4. Personal history of syncope of cardiovascular etiology, ventricular arrhythmia (of pathologic origin including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. 5. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade 2 or greater 6. Uncontrolled hypotension - Systolic BP \<90mmHg and/or diastolic BP \<50mmHg 7. Known left ventricular ejection fraction (LVEF) below lower limit of normal for site 8. Prior history of DVT/PE or embolic stroke, unless currently on therapeutic anticoagulation 9. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 1. Absolute neutrophil count \< 1.5 x 109/L 2. Platelet count \< 100 x 109/L 3. Hemoglobin \< 8 g/dL (Patients may receive transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.) 4. Alanine aminotransferase \> 3 times the upper limit of normal (ULN) 5. Aspartate aminotransferase \> 3 times ULN 6. Total bilirubin \> 1.5 times ULN (patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted) 7. Creatinine \>1.5 times ULN concurrent with creatinine clearance \< 50 ml/min (measured or calculated per local institutional practice); confirmation of creatinine clearance is only required when creatinine is \> 1.5 times ULN 8. Known proteinuria 3+ on dipstick analysis or \>500mg/24 hours 9. Sodium or potassium outside normal reference range
Conditions Metastatic Breast Cancer, Metastatic Sol...
Phase PHASE2
Enrollment 60
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment. 68Ga-ABS011 will be compared to the current standard of care (SOCa) diagnostic methods including immunohistochemistry (IHC), in situ hybridization (ISH) and imaging tools used for treatment response follow-up including Fluorodeoxyglucose F-18 (18F-FDG) positron emitted tomography (PET) and contrast enhanced computed tomography (ceCT).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 68Ga-NOTA-ABSCINT-HER2 PET/CT — 68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.

Primary Outcomes

  • positive, negative, and overall diagnostic agreement between 68Ga-ABS011 PET/CT and the standard of care IHC (and ISH) HER2 status test. (immediately after the 68Ga-ABS011 PET/CT procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-12
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abscint NV/SA
Principal Investigators:
  • Géraldine Gebhart (PRINCIPAL_INVESTIGATOR) - Institut Jules Bordet Brussels
  • Evandro De Azambuja (PRINCIPAL_INVESTIGATOR) - Institut Jules Bordet Brussels
Contact Information
Study Contact:
Karine Clauwaert
+32476536594
karine.clauwaert@abscint.com
Dieter Frijns
+32473337625
dieter.frijns@abscint.com
Daniel Egle, Prof.Dr.
0043 512 504 82477
ago.studienzentrale@i-med.ac.at
Medizinische Universität Innsbruck
Interventions
  • Diagnostic Test: 68Ga-NOTA-ABSCINT-HER2 PET/CT — 68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
Study Locations (7 sites)
Medizinische Universität Innsbruck, Innsbruck, Tyrol A-6020 Austria
AZ Delta CHIREC, Brussels, Brussels Capital 1070 Belgium
Cliniques Universitaires Saint-Luc, Brussels, Brussels Capital 1070 Belgium
Free University Brussels (VUB), Brussels, Brussels Capital 1070 Belgium
Institut Jules Bordet, Brussels, Brussels Capital 1070 Belgium
OLV Aalst, Aalst, East-Flanders 9300 Belgium
University Hospital Gasthuisberg, Leuven, Belgium
Eligibility Criteria
Inclusion Criteria: 1. Adult (≥ 18 years at the time of informed consent signature) male or female patient 2. Patient with confirmed de novo or pre-treated metastatic solid tumors (multiple previous treatment lines in metastatic setting are allowed). 2.1. Patients with documented hormone receptor positive/HER2 negative, triple-negative or HER2 positive mBC that could become eligible for commercially available HER2 targeted monotherapy (i.e. through confirmation of HER2 IHC non-0 status assessed during the course of the study) or 2.2 Other metastatic solid tumors, not necessarily eligible for commercially available HER2 targeted monotherapy . 3. Patient presenting with at least one target biopsiable, FDG positive , non-liver metastatic lesion of ≥15 mm defined on ceCT (as part of screening 18F-FDG PET/ceCT assessment). 4. Patient willing to undergo at least one tumor biopsy. 5. Male patients able to father children and female patients of childbearing potential agree to use effective methods of contraception during the diagnostic and SOCa treatment follow-up study phases. 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 7. Ability and willingness of the research participant to provide written informed consent. Exclusion Criteria: 1. Primary (non-metastatic) solid tumor cancer. 2. Patient not willing to undergo at least one tumor biopsy. Note: A recent biopsy and accompanied locally assessed IHC/ISH analyses, completed before screening, will not be accepted for study purposes. 3. 18F-FDG PET/ceCT completed before screening and patient not willing to repeat this assessment. 4. Metastatic setting 18F-FDG PET/ceCT indicating that the identified tumor lesions cannot be biopsied due their location and/or tissue type and/or an increased risk for serious comorbidities. 5. Brain and liver metastases are the sole sites of metastatic disease. 6. Life expectancy lower than 3 months. 7. Pregnancy or breastfeeding. 8. Inadequate organ function, suggested by clinically relevant abnormal laboratory results: 1. Significantly impaired renal function defined as estimated Glomerular Filtration Rate (GFR) \<30 ml/min/1.73m2. 2. Absolute neutrophil count \<1,500 cells/mm3. 3. Total bilirubin \~1.5 x Upper Limit of Normal (ULN) (unless the patient has documented Gilbert's syndrome). 4. Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or Alanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase (SGPT) \>5.0 x ULN. 9. Patients with a known hypersensitivity to any of the investigational medicinal product (IMP) components or packaging. 10. Patients with increased risks of bleeding or other complications from biopsies (e.g. patients under anticoagulation therapy for whom temporary discontinuation of this therapy cannot be safely performed). 11. Patients with a known hypersensitivity or contraindication for iodinated contrast media (iCM) which cannot be controlled by taking prophylactic measures (e.g. temporary treatment interruption or introduction of adequate pre-medication). 12. Patients who cannot undergo PET/CT scanning (including but not limited to body size and claustrophobia). 13. Any condition that in the opinion of the investigator may significantly interfere with study compliance (including but not limited to psychological or psychiatric, social or geographical condition potentially hampering compliance with the study requirements).
Conditions Stage 1 cT1b-T1cN0M0, Triple Negative Br...
Phase PHASE2
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Carboplatin — Given by IV
  • Drug: Paclitaxel — Given by IV
  • Drug: Pembrolizumab — Given by IV
  • Drug: Doxorubicin — Given by IV
  • Drug: Cyclophosphamide — Given by IV

Primary Outcomes

  • Safety and adverse events (AEs) (Through study completion; an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-05-29
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Oluchi Oke, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Oluchi Oke, MD
(832) 729-8362
oukaegbu@mdanderson.org
Oluchi Oke, MD
832-729-8362
oukaegbu@mdanderson.org
MD Anderson Cancer Center
Oluchi Oke, MD
MD Anderson Cancer Center
Interventions
  • Drug: Carboplatin — Given by IV
  • Drug: Paclitaxel — Given by IV
  • Drug: Pembrolizumab — Given by IV
  • Drug: Doxorubicin — Given by IV
  • Drug: Cyclophosphamide — Given by IV
Study Locations (1 sites)
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participants must have histologically confirmed ER negative, PR negative and HER2-negative (TNBC) defined as ER\<10%, PR\<10%, and HER2 negative (per 2018 ASCO CAP guidelines). All pathology will be confirmed at the MD Anderson Houston Campus. Participants with tumors designated as HER2 equivocal (per ASCO CAP guidelines) are eligible if in view of treating physician patient is not considered a candidate for HER2-targeted therapy. Participants with weakly ER or PR positive disease, defined as ER and/or PR between 1-9% by immunohistochemistry, are eligible if the treating physician considers the participants not eligible for adjuvant endocrine therapy. 2. AJCC 8 anatomic tumor Stage 1 T1b-T1c, N0, M0. All participants with clinically suspicious nodes must undergo core or fine needle biopsy per standard clinical practice to pathologically assess at least 1 suspicious index node. Participants with suspicious nodes that are biopsy negative will be eligible. 3. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of Stage 1 T1b-T1cN0M0 TNBC will be enrolled in this study. 4. Male participants: A male participant must agree to use a contraception as detailed in Appendix 2 of this protocol during the treatment period and for at least 120 days, corresponding to time needed to eliminate any study treatment(s) (e.g. 5 terminal half-lives for pembrolizumab and/or any active comparator/combination) plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose after the last dose of study treatment and refrain from donating sperm during this period. 5. Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 2), not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 2 OR 2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the treatment period and for at least 120 days (corresponding to time needed to eliminate any study treatment(s) (pembrolizumab and/or any active comparator/combination) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment. 6. Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible. 7. The participant provides written informed consent for the trial. 8. Archival tumor tissue sample or newly obtained \[core, incisional or excisional\] biopsy of a tumor lesion not previously irradiated has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. 9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 (appendix 3). Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention. 10. Have adequate organ function as defined in the following table (Table 3). Specimens must be collected within 10 days prior to the start of study intervention. 11. Non-English speaking participant can enroll in the study as long as they speak a language for which interpretation can be provided by a licensed interpreter either in person or virtually. 12. Criteria for known HIV positive participants. 1. Participants with HIV are eligible if they have well-controlled HIV with negative viral load on ART and must not have had any AIDS-defining opportunistic infections within the past 12 months from initiation of C1D1 study treatment. 2. HIV screening tests are not required unless: i. Known history of HIV ii. As mandated by local health authority 13. Criteria for known Hepatitis B and C positive participants Hepatitis B and C screening tests are not required unless: * Known history of HBV or HCV infection * As mandated by local health authority 13.1 Hepatitis B positive Participants * Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. * Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. 13.2 Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening. * Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization. Table 3 Adequate Organ Function Laboratory Values System Laboratory Value Hematological Absolute neutrophil count (ANC) = ≥1500/µL Platelets = ≥100 000/µL Hemoglobin = ≥9.0 g/dL or ≥5.6 mmol/La Renal Creatinine OR Measured or calculatedb creatinine clearance (GFR can also be used in place of creatinine or CrCl) = ≤1.5 × ULN OR ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN Hepatic Total bilirubin = ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 × ULN AST (SGOT) and ALT (SGPT) = ≤2.5 × ULN (≤5 × ULN for participants with liver metastases) Coagulation International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT) = ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal. a Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks. b Creatinine clearance (CrCl) should be calculated per institutional standard. Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: 1. Stage 2, 3 or 4 Triple negative breast cancer 2. Hormone Receptor positive and/or Human Epidermal Growth factor 2 (HER 2) positive breast cancer 3. A WOCBP who has a positive urine pregnancy test within 72 hours prior to dose of study drug (see Appendix 2). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 4. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137). 5. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks to allocation of therapy. 6. Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids. Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease, with a 1-week washout, is permitted. 7. Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed. 8. Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration. 9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of
Conditions TNBC - Triple-Negative Breast Cancer
Phase PHASE2
Enrollment 74
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: LM-108 — LM-108, 10mg/kg, d1, q6w
  • Drug: Toripalimab — Toripalimab, 240 mg, d1, q3w
  • Drug: Eribulin — Eribulin 1.4 mg/m2, d1, 8 , q3w
  • Drug: Nab paclitaxel — Nab paclitaxel 125 mg/m2, d1, 8 , q3w

Primary Outcomes

  • ORR (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-10
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Biyun Wang
18017312387
pro_wangbiyun@163.com
Biyun Wang
18017312387
pro_wangbiyun@163.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: LM-108 — LM-108, 10mg/kg, d1, q6w
  • Drug: Toripalimab — Toripalimab, 240 mg, d1, q3w
  • Drug: Eribulin — Eribulin 1.4 mg/m2, d1, 8 , q3w
  • Drug: Nab paclitaxel — Nab paclitaxel 125 mg/m2, d1, 8 , q3w
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years old (including boundary value), no gender limit; 2. ECOG score 0-1; 3. Expected survival ≥3 months; 4. Unresectable or metastatic or postoperative recurrent, histologically confirmed advanced triple-negative breast cancer. Triple-negative breast cancer is defined as: ER, PR and HER2 are negative. ER-negative and PR-negative are defined as tumors without positive staining, the proportion of cells in all tumor cells is \<1%; HER2-negative is defined as: HER2 (0), HER2 (1+) or HER2 (2+) detected by immunohistochemistry but negative by fluorescence in situ hybridization (FISH); Cohort 2 requires histological confirmation of PD-L1 CPS ≥ 1; 5. Cohort 1 : at least one prior line at recurrence or metastasis setting with disease progression or intolerable toxicity. In this situation, patients are allowed to be enrolled: the time between the last intravenous dose of adjuvant chemotherapy and first recurrence or metastasis is ≤6 months. Cohort 2: no prior line at recurrence or metastasis setting is allowed, the time between the last intravenous dose of adjuvant chemotherapy and first recurrence or metastasis ≥12 months.; 6. Provide sufficient fresh tissue specimens for biomarker analysis before treatment; 7. According to RECISTv1.1 standard, there is at least 1 measurable lesion; 8. Appropriate bone marrow and organ function before first dose : * Bone Marrow: Platelets ( PLT ) ≥ 90 × 109 /L , absolute neutrophil count ( ANC ) ≥ 1.5 × 109 /L , hemoglobin ≥ 9 g/dL ; * Coagulation: INR ≤ 1.5 , APTT ≤ 1.5 × ULN ; * Liver function: Liver function is basically normal, total bilirubin ≤ 1.5 × ULN ( total bilirubin in patients with Gilbert syndrome ≤ 3 × ULN can be enrolled), AST and ALT ≤ 2.5 × ULN (if there is liver metastasis, AST , ALT ≤ 5 × ULN ); * Renal function: serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (according to Cockcroft-Gault formula); * Cardiac function: left ventricular ejection fraction ( LVEF ) ≥ 50% ; female QT interval ( QTcF ) ≤ 470 ms , male ≤ 450 ms . 9. Be able to well communicate with the investigator and understand and comply with the requirements of this study. Exclusion Criteria: 1. Cohort 1 : Previous use of eribulin and CCR8- targeting drugs; Cohort 2: previous use of CCR8-targeting drugs and nab-paclitaxel, unless the interval between the last dose of nab-paclitaxel in the adjuvant chemotherapy and first recurrence or metastasis is ≥12 months; 2. Have received radiotherapy, chemotherapy, traditional Chinese medicine with anti-tumor indications, and local therapy (interventional therapy but not including tumor biopsy, ablation therapy, etc.) within 2 weeks before trial drug treatment; 3. Adverse events from previous anti-tumor treatments have not recovered to ≤ grade 1 according to CTCAE v5.0 (except for ≤ grade 2 toxicities judged by the investigator to have no safety risk, such as alopecia, long-term toxicity caused by radiotherapy, etc.); 4. Patients with known brain metastases. Those with stable brain metastases can be enrolled; 5. Third space effusion that is clinically uncontrollable and unsuitable for enrollment; 6. Participants with≥ grade 3 allergies to antibody drugs previously; 7. Taking systemic corticosteroids (\>10 mg daily prednisone or equivalent dose) or other systemic immunosuppressive drugs (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate , thalidomide, and anti-tumor necrosis factor drugs), topical, ocular, intra-articular, intranasal, and inhaled corticosteroids are allowed; 8. Subjects with a known history of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, Guillain-Barre syndrome, multiplex syndrome sclerosis or glomerulonephritis, except autoimmune-related hypothyroidism treated with stable dose of hormone; 9. Known idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, interstitial lung disease, severe radiation pneumonitis, or subjects with evidence of active pneumonia by chest CT scan screening.

FAST-FORWARD vs HAI5

NCT06345534
Recruiting
Conditions Cancer, Breast
Phase NA
Enrollment 740
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Randomized comparison between the FAST-FORWARD schedule and the HAI5 schedule for breast cancer radiotherapy in 5 fractions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Questionnaire — Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life. The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years.

Primary Outcomes

  • Early side effects (Weekly up to 6 weeks after radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-30
Completion: 2033-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 740 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Ghent
Principal Investigators:
  • Liv Veldeman, MD, PhD (PRINCIPAL_INVESTIGATOR) - UZ Ghent
Contact Information
Study Contact:
Liv Veldeman, MD, PhD
09 332 30 15
liv.veldeman@uzgent.be
Emma Van Damme
09 332 19 53
emma.vandamme@uzgent.be
Liv Veldeman, MD, PhD
09 332 30 15
liv.veldeman@uzgent.be
Universitary Hospital
Interventions
  • Device: Questionnaire — Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life. The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years.
Study Locations (2 sites)
Universitary Hospital, Ghent, 9000 Belgium
University Hospital Ghent, Ghent, 9000 Belgium
Eligibility Criteria
Inclusion Criteria: * histopathological diagnosis of breast cancer * age 18 years or older * male or female * treated with breast conserving surgery or mastectomy with curative intent * multidisciplinary decision of adjuvant radiotherapy after surgery Exclusion Criteria: * distant metastases * decision of preoperative radiotherapy * decision of partial breast irradiation * positive resection margins ('ink on tumour') * indication for boost on lymph node(s) * history of thoracic or ipsilateral axillary radiotherapy (including radiotherapy of the contralateral breast or chest wall) * need for bilateral irradiation * breast reconstruction or expander * patients unlikely to comply with the protocol (e.g. inability or unwillingness to complete the questionnaires at different time points).
Conditions Dietary Exposure, Diabetes Mellitus, Typ...
Phase Not Applicable
Enrollment 6000
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Cohort on Plant-based Diets (COPLANT) study is a multi-centre cohort study that starts baseline recruitment from 2024 to 2027 with approximately 6,000 participants in Germany and Austria. The COPLANT study focuses on vegan (no animal products), vegetarian (no meat and fish, but dairy products and eggs), pescetarian (no meat, but fish) and omnivorous (mixed diet including all possible animal products) diets. The aim of the COPLANT study is to gain new insights on health benefits and risks as well as social, ecological and economic effects of different plant-based diets in comparison to a mixed diet. In addition to a detailed dietary survey using an app adapted to the needs of this study, the baseline examination includes measurements of body composition, bone health, cardiovascular risk factors, diabetes risk, contaminants and lifestyle. For the basic laboratory program, fasting blood, 24-hour urine collection and a stool sample are taken from all study participants. Furthermore, specific aspects of dietary behavior, physical activity and other lifestyle factors are collected via questionnaires. Follow-up studies are planned at intervals of 5, 10 and 20 years after the baseline visit.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence of diabetes type 2 (5, 10, 20 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-09
Completion: 2047-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 6000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: German Federal Institute for Risk Assessment
Collaborators: Max Rubner-Institut, University of Bonn, Research Institute for Plant-Based Nutrition, University of Jena, University of Regensburg, Heidelberg University, University of Vienna
Principal Investigators:
  • Ute Nöthlings, Prof (PRINCIPAL_INVESTIGATOR) - University of Bonn
  • Christine Dawczynski, PhD (PRINCIPAL_INVESTIGATOR) - University Jena
  • Markus Keller, PhD (PRINCIPAL_INVESTIGATOR) - Research Institute for Plant-based Nutrition (IFPE)
Contact Information
Study Contact:
Cornelia Weikert, Prof
+49 30 184155000
Cornelia.Weikert@bfr.bund.de
Christine Dawczynski, PhD
+49 3641 949656
christine.dawczynski@uni-jena.de
Maria Wakolbinger, Prof
maria.wakolbinger@meduniwien.ac.at
University Vienna
Interventions
N/A
Study Locations (8 sites)
University Vienna, Vienna, 1090 Austria
Max Rubner-Institut, Karlsruhe, Baden-Wurttemberg 76131 Germany
Friedrich-Schiller University, Jena, Thuringia 07743 Germany
The German Federal Institut for Risk Assessment, Berlin, 10589 Germany
University Bonn, Bonn, Germany
Research Institute for Plant-Based Nutrition, Gießen, Giessen, 35444 Germany
University Heidelberg, Heidelberg, 69120 Germany
University Regensburg, Regensburg, 93053 Germany
Eligibility Criteria
Inclusion Criteria: * age between 18 and 69 years at recruitment (age-stratified recruitment in four age groups (18 to 29, 30 to 39, 40 to 49 and 50 to 69 years) which should be equally distributed across the four diets) * following their current diet for at least one year * health insured * are willing to have blood taken (adults) * are willing and able to complete questionnaires * only at Berlin, Jena, Giessen and Karlsruhe sites: pregnant and breastfeeding women were recruited (shortened examination programm) * only at the Regensburg, Heidelberg, Bonn and Vienna sites: are neither pregnant nor breastfeeding at the time of recruitment * only at Berlin and Karlsruhe sites: children of adult participants (shortened examination programm without collection of blood, urine, and stool) * are able to give informed consent to participate in the study * have given their consent to participate in the COPLANT study Exclusion Criteria: * who can no longer be contacted * who withdraw their consent to participate in the study